Menu Search
Equities

Applied DNA Sciences Inc

UDJ:BER

Applied DNA Sciences Inc

Actions
  • Price (EUR)0.25
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-98.52%
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2024 08:23 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.

  • Revenue in USD (TTM)3.40m
  • Net income in USD-7.52m
  • Incorporated2008
  • Employees53.00
  • Location
    Applied DNA Sciences Inc50 Health Sciences DriveSTONY BROOK 11790United StatesUSA
  • Phone+1 (631) 240-8800
  • Fax+1 (631) 240-8900
  • Websitehttps://adnas.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.